Company intelligence / Profile preview

NSPOH

Paramus, NJ, United Statesnspoh.nl ↗

Ownership: Private
Employees: ~124
Development stage: Other

Overview

NS Pharma has achieved commercial approval for viltolarsen in Duchenne muscular dystrophy and is advancing multiple therapies through late-stage clinical development. Its pipeline includes antisense oligonucleotides for various exons in DMD, gene therapies for rare diseases like MPS II and LCA1, a cell therapy partnered with Capricor Therapeutics, and a selective JAK1 inhibitor in Phase 2 trials for EGPA.

Therapeutic areas: ImmunologyOphthalmologyRare Diseases
Modalities: Antisense oligonucleotideGene therapyCell therapySmall molecule
Industry: Biotech

Partnerships

Capricor Therapeutics (for CAP-1002 cell therapy)

Beyond the preview

Go deeper on NSPOH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSPOH.

Explore the full profile